Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This is a phase II interventional trial to evaluate the efficacy of blinatumomab followed by
high-dose chemotherapy in the first-line treatment for Ph-negative acute lymphoblastic
leukemia (ALL) in adults. The aim is to increase the number of complete molecular responses
after first two cycles of therapy. Early molecular response is considered to be the most
powerful prognostic factor in ALL. Thus, a higher proportion of early molecular responses
should translate into improved survival and fewer indications for allogeneic stem cell
transplants
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Hematology and Blood Transfusion, Czech Republic
Collaborator:
CZECRIN - Czech Clinical Research Infrastructure Network